Patients with IBD could take drug holidays for COVID-19 protection
The GESA has published recommendations on managing IBD patients and colonoscopy deferral during the pandemic
Patients with IBD who are stable on immunosuppressants or biologic therapy could take a drug holiday to minimise their COVID-19 risk, it is now recommended.
On Thursday, the Gastroenterological Society of Australia (GESA) published its principles for IBD management and a guide to triaging endoscopic procedures during the pandemic.
“Patients on immunosuppression may be at higher risk if they contract COVID-19 infection, although that evidence is still emerging and is unclear,” they wrote.
“Patients should be continued on the minimum level of immunosuppressive or biologic therapy to control disease activity and minimise risk of flares.
